ArticleThe oncologist2019

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.

Toni K Choueiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.